Report cover image

Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 112 Pages
SKU # APRC20548513

Description

Summary

According to APO Research, The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global companies of Post-Polycythemia Vera Myelofibrosis (PPV-MF) include Novartis AG, Merck & Co Inc, AbbVie Inc, Sun Pharma Advanced Research Company Ltd, Promedior Inc, NS Pharma Inc, MEI Pharma Inc, MedImmune LLC and JW Pharmaceutical Corp, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Post-Polycythemia Vera Myelofibrosis (PPV-MF), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Post-Polycythemia Vera Myelofibrosis (PPV-MF).
The Post-Polycythemia Vera Myelofibrosis (PPV-MF) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Company

Novartis AG
Merck & Co Inc
AbbVie Inc
Sun Pharma Advanced Research Company Ltd
Promedior Inc
NS Pharma Inc
MEI Pharma Inc
MedImmune LLC
JW Pharmaceutical Corp
Italfarmaco SpA
Incyte Corp
Gilead Sciences Inc
F. Hoffmann-La Roche Ltd
CTI BioPharma Corp
Celgene Corp
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Type

Idelalisib
Givinostat
Glasdegib
Durvalumab
IMG-7289
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application

Hospital
Clinic
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Post-Polycythemia Vera Myelofibrosis (PPV-MF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post-Polycythemia Vera Myelofibrosis (PPV-MF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Post-Polycythemia Vera Myelofibrosis (PPV-MF) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

112 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Overview by Region 2020 VS 2024 VS 2031
1.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2020-2031)
1.4.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2020-2025)
1.4.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2026-2031)
1.5 Key Regions Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
1.5.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2020-2031)
1.5.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2020-2031)
1.5.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2020-2031)
1.5.4 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2020-2031)
1.5.5 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (2020-2031)
2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Type
2.1 Type Introduction
2.1.1 Idelalisib
2.1.2 Givinostat
2.1.3 Glasdegib
2.1.4 Durvalumab
2.1.5 IMG-7289
2.1.6 Others
2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Type
2.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Overview by Type (2020-2031)
2.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size Review by Type (2020-2025)
2.2.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecasted by Type (2026-2031)
2.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Regions
2.3.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2020-2025)
2.3.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2020-2025)
2.3.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2020-2025)
2.3.4 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2020-2025)
2.3.5 Middle East and Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Type (2020-2025)
3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Application
3.1 Type Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Application
3.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Overview by Application (2020-2031)
3.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size Review by Application (2020-2025)
3.2.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecasted by Application (2026-2031)
3.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Regions
3.3.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2020-2025)
3.3.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2020-2025)
3.3.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2020-2025)
3.3.4 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2020-2025)
3.3.5 Middle East and Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Breakdown by Application (2020-2025)
4 Global Market Dynamics
4.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends
4.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Drivers
4.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Opportunities and Challenges
4.4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Restraints
5 Competitive Insights by Company
5.1 Global Top Players by Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (2020-2025)
5.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Company Ranking, 2023 VS 2024 VS 2025
5.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Key Company Headquarters & Area Served
5.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company, Product Type & Application
5.5 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market CR5 and HHI
5.6.2 Global Top 5 and 10 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Market Share by Revenue in 2024
5.6.3 2024 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Tier 1, Tier 2, and Tier 3
6 Company Profiles
6.1 Novartis AG
6.1.1 Novartis AG Comapny Information
6.1.2 Novartis AG Business Overview
6.1.3 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.1.4 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.1.5 Novartis AG Recent Developments
6.2 Merck & Co Inc
6.2.1 Merck & Co Inc Comapny Information
6.2.2 Merck & Co Inc Business Overview
6.2.3 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.2.4 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.2.5 Merck & Co Inc Recent Developments
6.3 AbbVie Inc
6.3.1 AbbVie Inc Comapny Information
6.3.2 AbbVie Inc Business Overview
6.3.3 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.3.4 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.3.5 AbbVie Inc Recent Developments
6.4 Sun Pharma Advanced Research Company Ltd
6.4.1 Sun Pharma Advanced Research Company Ltd Comapny Information
6.4.2 Sun Pharma Advanced Research Company Ltd Business Overview
6.4.3 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.4.4 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.4.5 Sun Pharma Advanced Research Company Ltd Recent Developments
6.5 Promedior Inc
6.5.1 Promedior Inc Comapny Information
6.5.2 Promedior Inc Business Overview
6.5.3 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.5.4 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.5.5 Promedior Inc Recent Developments
6.6 NS Pharma Inc
6.6.1 NS Pharma Inc Comapny Information
6.6.2 NS Pharma Inc Business Overview
6.6.3 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.6.4 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.6.5 NS Pharma Inc Recent Developments
6.7 MEI Pharma Inc
6.7.1 MEI Pharma Inc Comapny Information
6.7.2 MEI Pharma Inc Business Overview
6.7.3 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.7.4 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.7.5 MEI Pharma Inc Recent Developments
6.8 MedImmune LLC
6.8.1 MedImmune LLC Comapny Information
6.8.2 MedImmune LLC Business Overview
6.8.3 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.8.4 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.8.5 MedImmune LLC Recent Developments
6.9 JW Pharmaceutical Corp
6.9.1 JW Pharmaceutical Corp Comapny Information
6.9.2 JW Pharmaceutical Corp Business Overview
6.9.3 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.9.4 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.9.5 JW Pharmaceutical Corp Recent Developments
6.10 Italfarmaco SpA
6.10.1 Italfarmaco SpA Comapny Information
6.10.2 Italfarmaco SpA Business Overview
6.10.3 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.10.4 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.10.5 Italfarmaco SpA Recent Developments
6.11 Incyte Corp
6.11.1 Incyte Corp Comapny Information
6.11.2 Incyte Corp Business Overview
6.11.3 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.11.4 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.11.5 Incyte Corp Recent Developments
6.12 Gilead Sciences Inc
6.12.1 Gilead Sciences Inc Comapny Information
6.12.2 Gilead Sciences Inc Business Overview
6.12.3 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.12.4 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.12.5 Gilead Sciences Inc Recent Developments
6.13 F. Hoffmann-La Roche Ltd
6.13.1 F. Hoffmann-La Roche Ltd Comapny Information
6.13.2 F. Hoffmann-La Roche Ltd Business Overview
6.13.3 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.13.4 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.13.5 F. Hoffmann-La Roche Ltd Recent Developments
6.14 CTI BioPharma Corp
6.14.1 CTI BioPharma Corp Comapny Information
6.14.2 CTI BioPharma Corp Business Overview
6.14.3 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.14.4 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.14.5 CTI BioPharma Corp Recent Developments
6.15 Celgene Corp
6.15.1 Celgene Corp Comapny Information
6.15.2 Celgene Corp Business Overview
6.15.3 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Global Share and Gross Margin (2020-2025)
6.15.4 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
6.15.5 Celgene Corp Recent Developments
7 North America
7.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
7.3 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2026-2031)
8 Europe
8.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
8.3 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2026-2031)
9 Asia-Pacific
9.1 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
9.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2026-2031)
10 South America
10.1 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
10.3 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2026-2031)
11 Middle East & Africa
11.1 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
11.3 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Forecast by Country (2026-2031)
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.